Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2911 - Cytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitis


10 Sep 2017


Poster display session


Cancers in Adolescents and Young Adults (AYA);  Supportive Care and Symptom Management;  Immunotherapy


Cindy Franklin


Annals of Oncology (2017) 28 (suppl_5): v403-v427. 10.1093/annonc/mdx376


C. Franklin1, I. Rooms1, M. Fiedler2, H. Reis3, L. Milsch1, S. Herz1, E. Livingstone1, L. Zimmer1, K.W. Schmid3, U. Dittmer2, D. Schadendorf1, B. Schilling1

Author affiliations

  • 1 Department Of Dermatology, Venerology And Allergology, University Hospital Essen, West German Cancer Centre, 45122 - Essen/DE
  • 2 Institute For Virology, University Hospital Essen, West German Cancer Centre, 45122 - Essen/DE
  • 3 Department Of Pathology, University Hospital Essen, West German Cancer Centre, 45122 - Essen/DE


Abstract 2911


Objectives: Immune checkpoint inhibitors have become a standard treatment in patients with metastatic malignant melanoma. Showing significant anti-tumor effects by unleashing the immune-system, checkpoint inhibitors can also cause high-grade immune-related adverse events, with immune-related diarrhea and colitis (irColitis) being amongst the most frequent ones. While the majority of patients with irColitis respond well when treated according to standard treatment algorithms with corticosteroids +/- other immunomodulatory drugs such as infliximab, some patients do not show resolution of diarrhea and colitis. In the present study, we analyzed the frequency of therapy-refractory irColitis, the underlying cause and useful diagnostic measures.


In this retrospective, monocenter study we collected data of 370 patients with metastatic malignant melanoma. All patients had been treated with checkpoint inhibitors at the skin cancer unit of the Department of Dermatology at the University Hospital Essen from 2006-2016. Demographic and clinical data of all patients were collected. Digital patient records of all 370 patients were searched for the terms “diarrhea” and “colitis”.


We identified 41 patients with irColitis, the majority occurring during treatment with ipilimumab. Amongst these patients, 5 (12.2%) were refractory to standard immunomodulatory treatment with corticosteroids and infliximab. Therapy-refractory cases tended to show more severe inflammation in colonic biopsies performed during colonoscopy (p = 0.04). CMV-DNA in colonic biopsies and in plasma was significantly more often detectable in therapy-refractory cases (80% vs. 6.75% in non-refractory cases in biopsies, 80% vs. 0% in plasma). Presence of serum CMV IgM as well as positive immunohistochemical stainings of colon biopsies for CMV were also strongly associated with refractory colitis (40% in refractory vs. 0% in non-refractory cases), but not reliable markers in the majority of refractory patients.


This report on CMV reactivation during management of checkpoint inhibitor induced colitis emphasizes the need for repetitive diagnostic measures in treatment-refractory irColitis.

Clinical trial identification

Legal entity responsible for the study

Ethics comittee of the University Hospital Essen, University of Diusburg-Essen




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.